New report for World Market for Cancer Therapeutics and Biotherapeutics by Kalorama Information
09 Jan 2012 • by Natalie Aster
A rising incidence of cancer, particularly in the over 50 population, is likely having a significant impact on all areas of cancer treatment. However, for many cancer types, there remains a significant unmet need in effective treatment. Lung cancer is one example, as patient survival is less than five years after diagnosis.
The report “World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition” by Kalorama Information focuses on several segments for cancer treatment including:
- Chemotherapy, - Subcategories include Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives - Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar, with Market Share for each
- Hormone Therapy: - Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS - Brands such as Arimidex, Casodex, Zoladex, Femara and Lupron, with Market Share for each
- Immunotherapy and Biotherapy, including: -Monoclonal antibodies, interleukins/interferons, vaccines and other biotherapies - Brands such as Rituxan, Herceptin, Gleevec, Evastin and Erbitux
World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition
Published: Oct, 2011
Price: US$ 3.500,00
One of the most promising new approaches in modern cancer treatment is immunotherapy or biotherapy, the development of methods to augment and enhance the body's natural tendency to defend itself against malignant tumors without damaging healthy tissue. The report devotes particular attention to these new therapies.
More information can be found in the report “World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition” by Kalorama Information.
To order the report or ask for sample pages contact [email protected]